Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life in patients with non-adipocyte soft tissue sarcoma
2017-003382-10Phase 4Terminated
- Sponsor
- GWT-TUD
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib, gemcitabine, doxorubicin, ifosfamide, dacarbazine and 6 more in soft tissue sarcoma (STS), sponsored by GWT-TUD. Primary endpoint: Overall quality of life. Started Nov 2017; status: terminated.
02
Drugs
pazopanibgemcitabinedoxorubicinifosfamidedacarbazine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2017-003382-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003382-10.